---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-014653"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-04-01T23:59:59+00:00"
generated_at: "2026-05-15T07:59:16.961665+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Q1 2026 CyPath Lung unit sales surge 146% YoY, beat projections

## Summary
- Q1 2026 CyPath Lung unit sales up 146% YoY, exceeding internal projections on accelerating physician adoption.
- Full-year 2025 CyPath Lung revenue rose 87% YoY, units sold up 99% vs 2024.
- Addressable U.S. market estimated at $3.58 billion; capturing 10% would represent $358M in sales.
- Company advancing large-scale clinical study and R&D pipeline for asthma/COPD diagnostics.

## SEC filing metadata
- accession: 0001493152-26-014653
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226014653/0001493152-26-014653-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226014653/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-014653
- JSON: https://secwatch.observer/filing/0001493152-26-014653.json
- Plain text: https://secwatch.observer/filing/0001493152-26-014653.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.